CAMP4 Therapeutics appoints two new directors, expands board to 12 members

Camp4 Therapeutics Corp

Douglas Williams, PhD and Murray Stewart, DM FRCP appointed as Class I and Class II directors, effective 3/17/25.
Board size increased from 10 to 12 members; Williams also appointed to Audit Committee.
Each new director granted option to purchase 17,787 shares under 2024 Equity Incentive Plan, vesting monthly over 3 years.
Standard indemnification agreements entered into; no prior transactions with company exceeding $120,000.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Douglas Williams

Class I Director

CAMP · Camp4 Therapeutics Corp

Effective: 2025-03-17
Filed: March 18, 2025, 7:59 PM ET

appointed Douglas Williams, PhD as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Douglas Williams was appointed as Class I Director at Camp4 Therapeutics Corp.

Action: appointed
Role: Class I Director

Exact text from the filing

appointed Douglas Williams, PhD as a Class I director

View on SEC.gov

Camp4 Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001736730-25-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.